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Summary Several reports have evaluated the correlation between cathepsin-D and overall survival or disease-free survival in node-negative
breast cancer patients. Because conflicting data have so far been reported, a meta-analysis was conducted to clarify this problem. Eleven
studies were included in our meta-analysis (total of 2690 patients). A specific meta-analytical methodology for censored data was used, and
disease-free survival was the primary end point. Patients with low cathepsin-D levels had a significantly better disease-free survival than
patients with high cathepsin-D values (meta-analytical odds ratio from 0.59 to 0.60 over the interval from 1 to 7 years). A secondary meta-
analysis conducted exclusively on the data from eight studies based on cytosol assay gave substantially similar results. One limitation of our
study is that the cut-off values to define high and low cathepsin-D concentrations were not identical in the various studies included in our
meta-analysis (range from 20 to 78 pmol mg-' protein), thus introducing a possible bias in the statistical analysis of the data. However, a
simulation based on the well-accepted method of the so-called publication bias showed that more than 100 null studies would be required to
lead our results to a statistical level of non-significance. Considering the results of our meta-analysis, we conclude that the data presently
available confirm a statistically significant association between high cathepsin-D values and poor disease-free survival in node-negative
breast cancer patients.
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The identification of new prognostic factors, more closely related
to tumour cell biology, would be of utmost importance for treat-
ment planning in human breast cancer. Improvement in discrimi-
nation between low- and high-risk cases is of major concern,
particularly in the subset ofnode-negative patients, 70% of whom
are cured by surgery alone and would therefore be spared the cost
and potential toxicity of adjuvant chemotherapy (McGuire, 1989;
Copper, 1991). To date, several biological factors have been
identified and proposed as potential prognostic indexes in human
breast cancer. Among these, particular attention has been focused
on proteolytic enzymes, such as cathepsin-D and urokinase-type
plasminogen activator, which are involved in basement
membrane/extracellular matrix degradation and tumour invasive-
ness and metastasis (Liotta et al, 1991).
Cathepsin-D, firstly identified as a 52-kDa oestrogen-regulated
glycoprotein (Westley et al, 1970), displays bothproteolytic activity
in culture and an autocrine mitogenic activity in breast cancer cells
(Vignon et al, 1986). The involvement of cathepsin-D in cancer
invasion is also supported by the demonstration that transfection of
cathepsin-D cDNA into rat tumorigenic cells increases their
metastatic potential in nude mice (Garcia et al, 1990). In addition,
higher cathepsin-D levels have been found in breast cancerpatients
with metastatic lymph node involvement than in node-negative
patients (Pujol et al, 1993; Winstanley etal, 1993; Gion et al, 1995).
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In recent years, great effort has been devoted to investigate the role
of cathepsin-D as a possible marker of tumour invasiveness and
poorprognosis, particularly innode-negative breast cancerpatients.
However, at present, the clinical usefulness of cathepsin-D
measurement remains controversial; evidence has been reported
that high cathepsin-D levels are associated with an unfavourable
prognosis in node-negative breast cancer patients (Spyratos et al,
1989; Thorpe et al, 1989; Tandon et al, 1990; Kute et al, 1992; Isola
et al, 1993), but some authors failed to find any relationship
between cathepsin-D and clinical outcome (Namer et al, 1991;
Kandalaft et al, 1993; Janicke et al, 1993; Pujol et al, 1993).
Inconsistency in the results may be due to variability of assay
techniques, criteria of patient classification, different cut-off
values ofcathepsin-D assay and also to the low statistical power of
individual studies that have often been conducted in relatively
small patient series.
Meta-analysis provides an efficient tool forcombining results of
independent studies, thus increasing statistical power and possibly
solving controversial issues.
In this report, we carried out a meta-analysis of the clinical
studies evaluating the prognostic value of cathepsin-D in node-
negative breast cancer patients.
MATERIALS AND METHODS
Literature search
We searched through the Iowa-IDIS compact disk database (Iowa
Drug Information System, Iowa City, USA; computer search from
January 1985 to September 1996) using 'cathepsin' and 'breast
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cancer' as index terms. This computer search was supplemented
by consulting Current Contents (Current Contents on Diskette,
Institute for Scientific Information, Philadelphia, USA; computer
search of diskettes from October 1991 to September 1996), the
Medline system on compact disk (Medline, Silver Platter
International, Norwood, MA, USA; computer search of diskettes
from January 1990 to September 1996), reviews, textbooks and
experts in this particular field of study. Additionally, we reviewed
all the references listed in the clinical studies that we found.
Meta-analysis protocol
The criteria for inclusion of the clinical studies into our meta-
analysis, as follows:
1. The clinical study regards patients with node-negative breast
cancer in whom the levels ofcathepsin-D were assayed at
staging.
2. The study provides separate follow-up data forpatients with
'high' or 'low' cathepsin-D values. The patient-specific end
point ofthe follow-up is the occurrence ofdisease relapse.
3. 'High' or 'low' cathepsin-D values are defined according to
cut-offvalues ranging from 20 to 78 pmol mg-' protein for
cytosol assays or according to semiquantitative methods for
immunohistochemical assays. Studies using cut-offvalues
outside this range are excluded unless specific (staging and
survival) data are available after patients' reclassification into
two subgroups according to a cut-offvalue included in our
accepted range.
Our meta-analysis of the disease-free survival data was
conducted using an 'actuarial survival methodology' (see below)
that requires the knowledge, for each study, of the number of
events (or relapses) stratified for each time interval of the follow-
up. As the information required by this type of meta-analysis
corresponds to the availability of individual patient data with
outcomes aggregated at follow-up intervals, an advantage of this
meta-analytical methodology lies in its intermediate nature
between meta-analyses of published data and meta-analyses of
individual patient data (Stewart and Parmar, 1993).
Statistical techniques
Survivalmeta-analysis
This statistical method [which has previously been used by
Gregory et al (1992), Messori et al (1994) and Berg et al (1994)]
was described originally by Peto (1987). In our study, this type of
meta-analysis was used to compare disease-free survival between
patients with high cathepsin-D values and patients with low
cathepsin-D values. All calculations were effected with a
microcomputer program [program META.EXE (Messori and
Rampazzo, 1993), Version 4.38]. According to Messori and
Rampazzo (1993), the final result generated by the disease-free
survival meta-analysis was denoted as 'log-rank odds-ratio' of
meta-analysis.
Ourprimary meta-analysis ofdisease-free survival included the
data of all clinical studies obtained from our literature search.
Then, a secondary meta-analysis was conducted using exclusively
the data ofstudies based on cytosol assays.
Otherstatistical calculations
Extraction ofrawsurvival data from the clinical studies
In order to carry out our survival meta-analysis, the survival
curves published in the various clinical studies were analysed by
the method of Fine et al (1993). This method allows one to
determine the distribution ofthe events and ofthe terminations of
follow-up (i.e. cases of 'right-censored patients') stratified for
each of the various time intervals of the follow-up. Controversial
cases (in which this method provided time-specific survival rates,
recomputed from raw data, that differed from the published
actuarial curves) were solved by contacting the study's authors.
The time intervals considered in this phase were the following:
(1) from randomization to 12 months; (2) from 12 to 24 months;
(3) from 24 to 36 months; (4) from 36 to48 months; (5) from48 to
60 months and (6) from 60 to 72 months.
Table 1 Studies included in the meta-analysis
Reference No. of patients Cut-off Positivity Assay Significance
according to (pmol mg-1 protein) (%) (P-value)
cathepsin-D content
Low High
Isola et al (1993)a 167 95 36 IHCI 0.0001
Janicke et al (1993) 64 33 50 34 ELSA 0.077
Kandalafi et al (1993)b 84 51 37.7 IHC 0.072
Kute et al (1992) 45 93 39 28 RIA 0.0001
Namer et al (1991) 132 114 35 46 ELSA NS
Pujol et al (1993) 38 26 20 40 ELISA 0.07
Seshadri et al (1994)c 117 237 25 67 ELSA NS
Ravdin et al (1994) 467 460 54 50 Western blot, IHC NS
Spyratos et al (1989) 39 29 45 42.6 ELISA 0.001
57 11 70 16 ELSA
Tandon et al (1990)e 135 64 75 32 Western blot 0.0001
Thorpe et al (1989)' 93 26 78 22 ELISA 0.06
Thorpe et al (1989)g 24 57 24 70 ELISA 0.039
aAt least 10% of strongly positive cells was used as cut-off value. bAuthors used an H-score (0-2 = low, 3-5 = high cathepsin-D content) derived from the
combination of a distribution score and an intensity score. cThese data, directly provided by Seshadri and co-workers (1994) refer to the patient group whose
follow-up information were updated to 31 May 1995. dThese data were directly provided by the authors. Ravdin et al (1994) also used an immunohistochemical
assay the results of which have not been considered herein. oThe cut-off used is 75 absorbance units. 'Subgroup of premenopausal patients. gsubgroup of post-
menopausal patients. hPercentage of patients with high cathepsin-D values. I1HC, immunohistochemistry.
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Calculation ofpooled rates In the survival meta-analysis, the RESULTS
pooled disease-free survival rates for the high cathepsin-D group
were estimated from the raw data using non-meta-analytical Literature search
actuarial methods (i.e. actuarial analysis of crude survival data Our literature search identified a total of 11 controlled clinical
stratified by time interval and summed over all studies). The pooled studies that met the inclusion criteria of our meta-analysis (Table
rates for low cathepsin group [with 95% confidence intervals (CIs)] 1). As regards the studies by Pujol et al (1993), by Seshadri et al
were computed by the method ofLaupacis et al (1988). (1994) and by Ravdin et al (1994), we obtained the disease-free
survival data of node-negative patients directly from the authors
Assessment of the inter-study heterogeneity There is a because these data were not explicitly reported in the published
growing agreement about the need to perform a heterogeneity articles. The Appendix summarizes the characteristics of the
assessment in all meta-analyses (Thompson, 1994). The inter- studies that were identified by our literature search but did not
study heterogeneity was estimated using the equations reported in meet the inclusion criteria ofthe meta-analysis.
the appendix of Collins et al (1985) and in Section 2.2.2 of
Messori and Rampazzo (1993). Meta-analysis including all studies
The results ofourmeta-analysis ofdisease-free survival are shown
Publication bias calculations The issue of publication bias in Table 2. The relative risk of relapse (expressed as odds ratios)
(Simes, 1987) was addressedby the procedure ofRosenthal (Klein was significantly different between patients with high vs low
et al, 1986), which is based on the estimation of the minimum cathepsin-D values.
number m of negative (or null) studies required to lead a In our primary meta-analysis, the assessment of inter-study
significant meta-analysis to non-significance. The value of m was heterogeneity gave a chi-square of91.6 (d.f. = 11, P = 0.001) at 84
calculated by the formula described by Klein et al (1986). The m months. These data show that the inter-study heterogeneity was
negative (or null) studies are hypothetical (simulated) trials in remarkably high.
which the two groups being compared are supposed to be identical The publication bias calculations indicated that the number of
in terms of outcome parameters. A highly significant meta- null studies needed to lead the meta-analysis results to levels of
analysis can be reversed to non-significance only by large values statistical non-significance was equal to 111 (estimate based onthe
ofm and vice versa. odds ratio at 60 months).
Table 2 Study-specific survival rates at 12, 24, 36, 48, 60, 72 and 84 monthsa and pooled rates generated by the survival meta-analysis according to
cathepsin-D status
Disease-free survival rates (%)a
At 12 months At 24 months At 36 months At 48 months At 60 months At 72 months At 84 months
Lowb Highb Low High Low High Low High Low High Low High Low High
Isola et al (1993) 92 85 87 74 81 60 80 54 74 49 69 49 69 47
Janicke et al (1993) 97 94 95 82 92 73 92 73 92 73 NA NA NA NA
Kandalaft et al (1993) 99 96 92 86 90 80 77 73 77 65 77 65 77 65
Kute et al (1992) 97 93 97 88 97 83 93 76 88 71 88 66 88 53
Namer et al (1991) 97 100 93 97 88 93 88 93 84 87 84 88 84 88
Pujol et al (1993) 100 92 97 84 94 76 92 76 92 76 92 76 NA NA
Ravdin et al (1994) 95 96 90 89 84 80 82 77 78 73 75 70 71 70
Seshadri et al (1994) 98 96 96 88 89 83 84 82 81 79 78 78 60 78
Spyratos et al (1989) 100 96 97 96 94 79 94 68 94 62 81 31 81 31
Tandon et al (1990) 96 83 90 71 81 57 78 53 71 47 71 47 NA NA
Thorpe et al (1989)c 90 81 82 65 77 53 69 45 69 45 69 45 69 45
Thorpe et al (1989)d 96 89 96 83 91 77 86 73 86 69 85 69 85 69
Pooled rates (%) 97.4 94.0 95.6 86.4 90.2 78.6 86.8 75.1 83.2 71.1 80.8 69.1 79.5 68.1
95% Cl (94.7-100) (91.5-100) (85.8-94.8) (82.6-91.3) (78.9-87.5) (76.6-85.1) (75.3-83.7)
Relative risk of relapsee 0.62 1 0.53 1 0.55 1 0.57 1 0.59 1 0.60 1 0.61 1
(95% Cl) (0.43-0.89) - (0.41-0.69) - (0.45-0.69) - (0.47-0.69) - (0.49-0.70) - (0.51-0.72) - (0.52-0.73) -
z' 2.58 4.87 5.67 5.77 5.89 5.74 5.56
Statistical significance' P= 0.01 P < 0.001 P<0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
aTo ensure the homogeneity of calculations, these study-specific rates were all recomputed from the survival data generated by the application of Fine's method
(1993). This recomputation was made using Equation 4b of Kaplan and Meier (1958). b'Low' and 'High' refer to cathepsin-D content. cSubgroup of
premenopausal patients. dSubgroup of post-menopausal patients. *The relative risk, estimated as log-rank odds ratios and the statistical comparisons refer to
the whole period from time zero to the individual timepoint. 'These values refer to the meta-analytical comparisons between the high cathepsin-D and the low
Cathepsin-D groups made at the various time-points of the follow-up.
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This assessment of publication bias tested the hypothesis of a
greater likelihood of positive studies being published, but obvi-
ously could not check the stability ofour results against the likeli-
hood that the results of some studies might have been inflated by
the use of an optimum cut-offpoint.
The data of Spyratos et al (1989) were introduced in our meta-
analysis using the cut-off of 45 pmol mg-'. In a separate analysis
(data not shown), we checked that the results ofour meta-analysis
remain virtually unchanged using the cut-off of 70 pmol mg-'
reported by Spyratos et al (1989).
Meta-analysis including cytosol-based studies
The eight papers by Pujol et al (1993), Spyratos et al (1989), Kute
et al (1992), Namer et al (1991), Janicke et al (1993), Tandon et al
(1990), Seshadri et al (1994) and Ravdin et al (1994) (Table 1)
were included in this secondary meta-analysis focused on studies
using cytosol assays. The results were very similar to those
produced by the first meta-analysis. Statistical significance was
slightly less marked (value at 24 months: z = 3.96, P <0.001; value
at 48 months: z = 4.36, P < 0.001; value at 72 months: z = 4.61,
P < 0.001); the values of odds ratios at the various times were all
around 0.60 (value at 24 months: 0.56 with 95% CI of 0.42-0.75;
value at 48 months: 0.62 with 95% CI of 0.50-0.77; value at 72
months: 0.63 with 95% CI of0.52-0.77). Interestingly enough, the
level of inter-study heterogeneity showed no decrease after the
exclusion of studies using immunohistochemical techniques.
DISCUSSION
To our knowledge, this is the first study in which the possible prog-
nostic role of a biological factor has been evaluated by means of
a meta-analytical approach based on survival methodology. One
advantage of the meta-analytical approach is that it enables the
circumvention ofthe lack of statistical power as a result of the rela-
tively small sample size ofmany studies. The choice to carry out this
meta-analysis on the prognostic role of cathepsin-D in node-
negative breast cancer patients stems from the following reasons:
(1) evidence has been reported about the direct relationship of
cathepsin-D with tumour cell invasiveness and metastatic behaviour
(Garcia et al, 1990; Pujol et al, 1993; Winstanley et al, 1993; Gion et
al, 1995); (2) cathepsin-D has been included among the biological
factors potentially useful for discrimination between high- and low-
risk patients to avoid adjuvant overtreatment in the latter group
(Bevilacqua et al, 1994); (3) although the negative prognostic role of
high cathepsin-D levels in node-negative breast cancer patients has
been demonstrated by several authors (Spyratos et al, 1989; Thorpe
et al, 1989; Tandon et al, 1990; Kute et al, 1992; Isola et al, 1993),
conflicting results have also been reported (Namer et al, 1991;
Kandalaft et al, 1993; Janicke et al, 1993; Pujol et al, 1993). Our
study demonstrated that elevated cathepsin-D values identify node-
negative breast cancer patients characterized by unfavourable prog-
nosis in terms of disease-free survival. Although heterogeneity of
the studies as well as different definitions of cathepsin-D positivity
might have been a source ofbias, the exclusion of studies analysing
cathepsin-D content by immunohistochemistry did not change the
statistical significance of our meta-analytical results. Moreover,
despite a certain degree of heterogeneity in the percentage of
cathepsin-D positivity, our publication bias simulations demon-
strated that more than 100 null studies would be required to reverse
our results to the level ofstatistical non-significance.
It should be noted that several reports could not be included in
our meta-analysis because of the incomplete presentation of
survival curves. This fact emphasizes the need for studies dealing
with the assessment of potentially prognostic biological factors
to ensure a sufficient level of reporting of the results to allow
reappraisal in meta-analysis studies.
It has been suggested that the relationship of total tumour
cytosolic cathepsin-D to adverse prognosis may be impaired by
the presence of cathepsin-D in non-epithelial cells. In particular,
it has been found that stromal and macrophage-like cells are
cathepsin-D positively immunostained in approximately 35% of
cases defined as negative according to tumour cell immunoreac-
tions irrespective of the use of monoclonal (Isola et al, 1993) or
polyclonal (Domagala et al, 1992) antibodies. However, Roger et
al (1994) reportedthatcytosolic cathepsin-D levels correlated with
cathepsin-D expression in cancer cells, and several studies agree
with the finding that cathepsin-D contents in stromal and cancer
cells are directly correlated (Isola et al, 1993; Eng Tan et al, 1994;
Ravdin et al, 1994).
On the other hand, results obtained by immunohistochemistry
showed the highest degree of heterogeneity, probably because of
differences in the antibodies used and in cathepsin D positivity
criteria (see Table 2); some studies demonstrated the adverse prog-
nostic role of tumour cell cathepsin-D content (Isola et al, 1993;
Winstanley et al, 1993; Roger et al, 1994), while others failed to
find any relationship between tumour cell cathepsin-D expression
and clinical outcome (Domagala et al, 1992; Kandalaft et al, 1993;
Armas et al, 1994) and only one (Henry et al, 1990) showed a
favourable impact of tumour cell cathepsin-D on prognosis.
Ravdin et al (1994) suggested that cathepsin-D assessment by
Western blot should not be routinely used for the prognostic char-
acterization ofbreast cancerpatients.
Although a general consensus on the routine use of this tech-
nique is still far from being achieved, the assessment ofcathepsin-
D contentby means ofimmunoradiometric assay seems tobe likely
to give morereliable andcomparable inter-study results as assessed
by the EORTC Receptor Study Group (Benraad et al, 1992).
One limitation ofour study is that the cut-offvalues that differ-
entiate between high and low cathepsin-D concentrations were not
identical in the various studies but varied from 20 to 78 pmol mg-'
protein. While this factcould have introduced abias increasing the
statistical significance of our results, the high number of null
studies required in our publication bias assessment to reverse our
results to non-significance supports the conclusion ofour analysis.
We cannot rule out the possibility that some of the studies
included in our analysis might have been influenced by the
selection of an optimum cut-off point, but the overall evidence
emerging from our study seems to be sufficient to support the
conclusion that cathepsin-D has aprognostic role in these patients.
In their paper that suggested a poor correlation between prog-
nosis and cathepsin-D levels, Ravdin et al (1994) conducted an
exploratory analysis on different cathepsin-D cut-off values
wherein these cut-off values were retrospectively varied over the
range from 1 to 1000 units. This analysis showed that the
'optimum' cut-off value (i.e. the value of Cathepsin-D that
produced the highest statistical correlation with aP-value of0.009)
was around 22 units. Furthermore, Ravdin et al (1994) tried to
ascertain to what extent this retrospective identification of the
optimum cut-off could have contributed to an artifactual P-value
*An analytical printout ofthe survival data ofthe clinical studies included in our
meta-analysis is avallable from the authors upon request.
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(i.e. to an overestimation ofthe statistical significance ofthe corre-
lation between cathepsin-D levels and prognosis) and to what
extent their findings, which revealed this apparent correlation using
the retrospective cut-off of 22 units, could be compatible with a
purely casual result (i.e. a result derived from a simulated popula-
tion wherein the correlation was totally absent). This latter analysis
of Ravdin et al (1994), which was based on the simulation ofabout
300 different data sets, showed that there was a one in six chance
that the high correlation found in the primary analysis was purely
casual. The authors therefore concluded that their hypothesis of a
'true' correlation was not supported by sufficient evidence and that
the apparent cut-offpoint found retrospectively in theirreal data set
was likely to be casual.
While these conclusions proposed by Ravdin et al (1994), after
analysis of their data, are perhaps too conservative, it should be
stressed that the findings reported by these authors are however
consistent with a correlation at P-levels of about 0.10 or 0.20 and
therefore suggest at least the presence ofa statistical trend.
To better interpret the results ofourmeta-analysis, we tried to plan
a simulation based on the comparison of a hypothetical population
with no correlation vs our real patient population. Unfortunately, the
lack ofindividual patient data on cathepsin D assays did not allow us
to produce reliable statistical results on this point.
Another controversial point regards the methodology of the
survival meta-analysis used in our study. Because there is
presently no consensus on which methodology should be recom-
mended for survival meta-analysis, we analysed all survival data
included in our study using a different method of survival meta-
analysis (Simes, 1987) in which median survival is used for
comparing two patient groups with one another across a series of
different clinical studies. This further analysis (data not shown)
produced essentially the same results obtained by our primary
survival meta-analysis.
Therefore considering the results of our primary meta-analysis
(together with the relatively low inter-study difference in the cut-
off values and the results of our publication bias assessments), we
conclude that the data presently available confirm a statistically
significant association between cathepsin-D and disease-free
survival in breast cancer.
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APPENDIX 1: OVERVIEW OF THE STUDIES
IDENTIFIED BY OUR LITERATURE SEARCH AND
NOT INCLUDED IN THE META-ANALYSIS
Some studies that were extractedby ourliterature search [namely the
studies by Winstanley et al (1993), Domagala et al (1992), Eng Tan
et al (1994), Henry et al (1990), Romain et al (1990), Joensuu et al
(1995), Armas et al (1994), Aaltonen et al (1995) and Bevilacqua et
al (1994)] were notincluded inthemeta-analyses forseveralreasons.
The studies by Domagala et al (1992), Joensuu et al (1995),
Armas et al (1994) and Aaltonen et al (1995), which used
immunohistochemical methods, reported the actuarial curve of
overall survival but not the disease-free survival curve; thus, these
studies did not present the data needed for our analysis. Contrary
to the data reported by Joensuu et al (1995) and Armas et al
(1994), the results of Domagala et al (1992) and Aaltonen et al
(1995) were however in agreement with the results of our meta-
analysis because these authors found a trend in node-negative
patients favouring the subgroup with low cathepsin-D values.
The studies by Romain et al (1990) did not present the disease-
free survival curves in node-negative patients needed forinclusion
in our analysis. Overall survival was better in the low-cathepsin-D
content group (rate of 1 out of 12, cut-offof50 pmol mg' protein
by cytosol assay) than in the high-cathepsin-D content group (rate
of 4 out of 22); these figures however refer to the overall patient
group, irrespective ofnode status.
Likewise, Winstanley et al (1993) and Bevilacqua et al (1994),
who reported the survival curve oftheir patients without stratifica-
tion by node status, found a survival trend in favourofpatients with
low cathepsin-D content as assessed by immunohistochemistry.
Eng-Tan et al (1994), who used both an immunohistochemical
assay and a cytosol technique (with the cut-off value of
70 pg mg-' protein), found no significant prognostic value of
cathepsin-D. No curves of overall survival or disease-free
survival were reported.
The immunohistochemical study by Henry et al (1990) is
atypical in that an inverse trend in the disease-free survival was
found because patients with high cathepsin-D values had better
disease-free survival than patients with low cathepsin-D. This
analysis was not stratified by node status, and so the disease-free
curve of node-negative patients needed for our analysis was not
available. As the study by Henry et al (1990) involved a relatively
small patient population (62 subjects with high cathepsin-D
content vs 32 subjects with low cathepsin-D content), it can
reasonably be concluded that the impact ofits exclusion from our
meta-analysis was very small.
The size ofthe patient population included in these studies was
the following (the figures that are reported below refer to the total
number of patients examined in each individual trial, i.e. the sum
of the number of patients with high cathepsin-D plus the number
of patients with low cathepsin-D): Winstanley et al (1993), n =
130; Domagala et al (1992), n = 77; Eng Tan et al (1994), n = 214;
Henry et al (1990), n = 62; Romain et al (1990), n = 40; Joensuu et
al (1995), n = 213; Armas et al (1994), n = 153; Aaltonen et al
(1995), n = 151; Bevilacqua et al (1994), n = 82.
Our literature search identified only one study [conducted by
Romain et al (1990)] written in non-English language.
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